Compare YieldMax Universe Fund of Option Income ETFs (YMAX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Universe Fund of Option Income ETFs vs Zoetis Inc — how do they compare? YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 83× YieldMax Universe Fund of Option Income ETFs's market cap, and Zoetis Inc pays a 2.9% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Universe Fund of Option Income ETFs for 56 Days and Zoetis Inc for 70 Days on average.
| YMAX | ZTS | |
|---|---|---|
Market Cap | $364M | $30.20B |
Volume | 1,181,378 | 6,175,327 |
Sector | Income / Options Overlay | Health |
52-Week High | $12.98 | $147.53 |
52-Week Low | $7.27 | $69.09 |
Typical Hold Time | 56 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
YMAX trades at $7.48, down 0.66% with a bearish technical outlook showing 18 sell signals versus 2 buy signals. The ETF faces fundamental challenges with declining NAV and concerns about distribution sustainability despite offering high yields. Recent news highlights weekly dividend distributions but also raises questions about the fund's structure and cost efficiency.
The outlook remains cautious due to persistent NAV erosion and structural concerns. While the high distribution yield attracts income investors, the fund's declining share price and potential for reverse splits present significant risks. Investors should weigh the attractive income against the potential for principal erosion in this complex ETF structure.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
